Clinical trials: Alzheimer Disease 1
Alzheimer's Disease
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
The purpose of this study is to evaluate the safety and tolerability of dimebon given to Alzheimer's disease patients currently on a stable dose and regimen of memantine or memantine plus donepezil.
- Trial name
- NCT00829816
- Testing
- Dimebon
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Medivation, Inc.
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Alzheimer's Disease
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo.
- Trial name
- NCT01193608
- Testing
- AAB-003 (PF-05236812)
- Where
- 29 sites in United States, South Korea
- Volunteers
- 88 people
- Sponsor
- Pfizer
Bird Flu, Influenza
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1
The purpose of this study is to compare the safety and immunogenicity over a 9-month period of five different dosages of Ad4-H5-Vtn in volunteers (Vaccinees) who receive three doses of the study vaccine or placebo.
- Trial name
- NCT01006798
- Testing
- Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1
- Where
- 4 sites in United States
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Alzheimer Disease
Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants
This First-in-human (FIH) study will evaluate the safety, tolerability, and pharmacokinetics of the tau self-association inhibitor, OLX-07010 in single ascending doses (SAD) and multiple ascending doses (MAD) in healthy adults…
- Trial name
- NCT05696483
- Testing
- OLX-07010 Active
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Oligomerix, Inc
Alzheimer Disease, Agitation,Psychomotor
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from…
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
- Trial name
- CALMA (NCT05543681)
- Testing
- IGC-AD1-Active
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 164 people
- Sponsor
- IGC Pharma, LLC
Alzheimer Disease
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia…
- Trial name
- NCT05834296
- Testing
- ALZN002 (autologous DCs pulsed with E22W mutant peptide).
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alzamend Neuro, Inc.
Alzheimer's Disease
Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
The purpose of the study is to examine the safety and tolerability of a multiple dose of PF-04360365 administered over approximately 10 minutes in Japanese patients with mild-to-moderate Alzheimer's disease and to characterize…
- Trial name
- NCT01125631
- Testing
- PF-04360365 8.5 mg/kg
- Where
- 4 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Pfizer
Alzheimer Disease
Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease
This study is a Phase 1, first-in-human, multi-center study to establish safety of ADx-001 in healthy volunteers, and safety and proof of concept in patients with confirmed amyloid plaques in the brain (confirmed by amyloid…
- Trial name
- NCT05453539
- Testing
- DSPE-DOTA-Gd Liposomal Injection
- Where
- 2 sites in Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Alzeca Biosciences, Inc.
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Alzheimer Disease
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when…
- Trial name
- INTERCEPT-AD (NCT04931459)
- Testing
- ACU193
- Where
- 17 sites in United States
- Volunteers
- 65 people
- Sponsor
- Acumen Pharmaceuticals
Alzheimer's Disease
Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects
This is a Phase 1, Randomized, Placebo-Controlled, Double-Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects.
- Trial name
- NCT01467726
- Testing
- Velusetrag
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alfasigma S.p.A.
Alzheimer's Disease
Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers
Phase 1A SAD: Five or more cohorts of 8 healthy volunteers (HVs) will receive a single IV bolus injection of study drug or placebo. The first 4 cohorts will be male only.
- Trial name
- NCT05965414
- Testing
- CS6253 Solution for Injection
- Where
- Spain
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Artery Therapeutics, Inc.
Alzheimer Disease (AD)
Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease
The study aims to compare tau targeted radiotracers [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in subjects with normal cognition or prodromal to moderate Alzheimer's disease (AD).
- Trial name
- NCT04566003
- Testing
- [18F]GTP1, [18F]PI-2620, [18F]MK-6240
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.
Alzheimer Disease
A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®
A Phase 1, Randomized, Open-Label, 3-Way Crossover, Pilot, Pharmacokinetic Study to Evaluate the Steady State Pharmacokinetics of a Once-Weekly Application of Corplex Donepezil Transdermal Delivery System (TDS) Compared to Daily…
- Trial name
- NCT02968719
- Testing
- Donepezil TDS Version A, Donepezil TDS Version B, Aricept
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Corium, Inc.
Healthy Participants, Alzheimer Disease
A Phase 1 Study to Assess the Safety and Effects of Single and Multiple Doses of KS101 in Healthy Volunteers
This study is the first clinical trial involving study drug KS101. The goal of this clinical trial is to investigate whether KS101 is safe, whether it causes side effects, and how KS101 is broken down in the body, in healthy…
- Conditions
- Healthy Participants, Alzheimer Disease, Chronic Kidney Disease
- Trial name
- NCT07143331
- Testing
- Part 1 KS101, Part 2 with Food, Part 2 without food
- Where
- Australia
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Klotho Sciences Australia Pty Ltd.
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children with Atopic Dermatitis. This is a randomized, double-blind, Vehicle Controlled study.
- Trial name
- NCT04921969
- Testing
- Ruxolitinib, Vehicle Cream
- Where
- 67 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Alzheimer Disease
A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects
The purpose of this study is to evaluate the PK, safety, and tolerability of a new liquid formulation of tricaprilin.
- Trial name
- NCT05408780
- Testing
- AC-OLE-01-VA
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Cerecin
Healthy Volunteers
A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
The purpose of this healthy volunteers drug-drug interaction study is to assess the CYP1A2 and CYP3A4 perpetrator interaction potential and CYP1A2 victim potential of TEV-56286 (anle138b).
- Trial name
- NCT05532358
- Testing
- anle138b (TEV-56286), Fluvoxamine 100 mg QD for 5 days
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06980207
- Testing
- LY03017
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.